CompletedPHASE1, PHASE2NCT03131999

LAM Pilot Study With Imatinib Mesylate

Studying Lymphangioleiomyomatosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Medical University of South Carolina
Principal Investigator
Christopher Meinberg
Congressionally Directed Medical Research Programs
Intervention
Imatinib Mesylate 400Mg Capsule(drug)
Enrollment
18 enrolled
Eligibility
18 years · All sexes
Timeline
20182019

Study locations (2)

Collaborators

Columbia University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03131999 on ClinicalTrials.gov

Other trials for Lymphangioleiomyomatosis

Additional recruiting or active studies for the same condition.

See all trials for Lymphangioleiomyomatosis

← Back to all trials